These advanced treatments combine the targeted precision of monoclonal antibodies with the potent cytotoxicity of chemotherapeutic agents, enhancing drug delivery to HER2-overexpressing tumor cells, thereby maximizing therapeutic efficacy while minimizing off-target effects. This evidence concerns the gene ERBB2 and neoplasm.